Efficacy and safety of desloratadine in adults with chronic idiopathic urticaria: A randomized, double-blind, placebo-controlled, multicenter trial

American Journal of Clinical Dermatology

Volumn 8, Issue 1, 2007, Pages 37-42

  Ortonne, Jean Paul ^a   Grob, Jean Jacques ^b   Auquier, Pascal ^c   Dreyfus, Isabelle ^d  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^b Esthétique et Laser de Marseille   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d Schering Plough   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DESLORATADINE; PLACEBO; DRUG DERIVATIVE; HISTAMINE H1 RECEPTOR ANTAGONIST; LORATADINE;

ADULT; ARTICLE; CHRONIC URTICARIA; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; UNSPECIFIED SIDE EFFECT; CHRONIC DISEASE; DOSE RESPONSE; HOSPITALIZATION; MIDDLE AGED; TREATMENT OUTCOME; URTICARIA;

ADULT; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; LORATADINE; MALE; MIDDLE AGED; PRURITUS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; URTICARIA;

EID: 34247242642     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200708010-00005     Document Type: Article

References (28)

1. Greaves MW. Chronic urticaria. N Engl J Med 1995; 332 (26): 1767-72
2. O'Donnell BF, Lawlor F, Simpson J, et al. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997; 136 (2): 197-201
3. Kozel MMA, Sabroe RA. Chronic urticaria: aetiology, management and current and future treatment options. Drugs 2004; 64 (22): 2515-36
4. Ring J, Hein R, Gauger A. Desloratadine in the treatment of chronic idiopathic urticaria. Allergy 2001; 56 Suppl. 65: 28-32
5. Sabroe RA, Greaves MW. The pathogenesis of chronic idiopathic urticaria. Arch Dermatol 1997; 133 (8): 1003-8
6. Kaplan AP, Horáková Z, Katz SI. Assessment of tissue fluid histamine levels in patients with urticaria. J Allergy Clin Immunol 1978; 61 (6): 350-4
7. Monroe E, Finn A, Patel P, et al. Efficacy and safety of desloratadine 5mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol 2003; 48 (4): 535-41
8. Sabroe RA, Poon E, Orchard GE, et al. Cutaneous inflammatory cell infiltrate in chronic idiopathic urticaria: comparison of patients with and without anti-FcεRI or anti-IgE autoantibodies. J Allergy Clin Immunol 1999; 103 (3 Pt 1): 484-93
9. Gruber BL, Baeza ML, Marchese MJ, et al. Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes. J Invest Dermatol 1988; 90 (2): 213-7
10. Grattan CEH, Francis DM, Hide M, et al. Detection of circulating histamine releasing autoantibodies with functional properties of anti-IgE in chronic urticaria. Clin Exp Allergy 1991; 21 (6): 695-704
11. Hide M, Francis DM, Grattan C, et al. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med 1993; 328 (22): 1599-604
12. Zweiman B, Valenzano M, Atkins PC, et al. Characteristics of histamine-releasing activity in the sera of patients with chronic idiopathic urticaria. J Allergy Clin Immunol 1996; 98 (1): 89-98
13. Tong LJ, Balakrishnan G, Kochan JP, et al. Assessment of autoimmunity in patients with chronic urticaria. J Allergy Clin Immunol 1997; 99 (4): 461-5
14. Metzger H. The high affinity receptor for IgE on mast cells. Clin Exp Allergy 1991; 21 (3): 269-79
15. Schwartz LB. Mast cells and their role in urticaria. J Am Acad Dermatol 1991; 25 (1 Pt 2): 190-204
16. Maxwell DL, Atkinson BA, Spur BW, et al. Skin responses to intradermal histamine and leukotrienes C4, D4, and E4 in patients with chronic idiopathic urticaria and in normal subjects. J Allergy Clin Immunol 1990; 86 (5): 759-65
17. Zuberbier T, Bindslev-Jensen C, Canonica W, et al. EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy 2006; 61 (3): 316-20
18. Zuberbier T, Bindslev-Jensen C, Canonica W, et al. EAACI/GA2LEN/EDF guideline: management of urticaria. Allergy 2006; 61 (3): 321-31
19. Yosipovitch G, Ansari N, Goon A, et al. Clinical characteristics of pruritus in chronic idiopathic urticaria. Br J Dermatol 2002; 147 (1): 32-6
20. Ring J, Brockow K, Ollert M, et al. Antihistamines in urticaria. Clin Exp Allergy 1999; 29 Suppl. 1: 31-7
21. 1-receptor antagonist drugs. J Allergy Clin Immunol 1996; 98 (6 Pt 3): S307-18
22. Ng KH, Chong D, Wong CK, et al. Central nervous system side effects of first- and second-generation antihistamines in school children with perennial allergic rhinitis: a randomized, double-blind, placebo-controlled comparative study. Pediatrics 2004; 113 (2): e116-21
23. Simons FER. Advances in H1-antihistamines. N Engl J Med 2004; 351 (21): 2203-17
24. Ring J, Hein R, Gauger A, et al. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int J Dermatol 2001; 40 (1): 72-6
25. Baiardini I, Pasquali M, Braido F, et al. A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-QoL). Allergy 2005; 60 (8): 1073-8
26. Murdoch D, Goa KL, Keam SJ. Desloratadine: an update of its efficacy in the management of allergic disorders. Drugs 2003; 63 (19): 2051-77
27. Di Lorenzo G, Pacor ML, Mansueto P, et al. Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria. J Allergy Clin Immunol 2004; 114 (3): 619-25
28. Nettis E, Colanardi MC, Paradiso MT, et al. Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study. Clin Exp Allergy 2004; 34 (9): 1401-7